Technology And Equipment Tenders

Corrigendum: Drug Discount Contracts with Membership Option - 0071-Rvbeitr.65-2023

Open House Originals Discount Agreements 2023-40 - Baricitinib

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Ambrisentan (Atc Code According to Who: C02kx02)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Flecainide (Atc Code According to Who: C01bc04)

Open House Biologics Discount Agreements 2023-27 - Eculizumab

Drug Contracts with Accession Option

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Glatiramer Acetate (Atc Code According to Who: L03ax...

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Pipamperone (Atc Code According to Who: N05ad05)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V by Means of an Open House Model for the Active Ingredient Leuprorelin (Atc Code According to Who: L02ae02)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Tocilizumab (Atc Code According to Who: L04ac07)